Abstract
Many Gram-negative bacteria share a closely related mechanism for secretion of virulence proteins. This complex machine, the type III secretion system, secretes virulence proteins in response to sensing the presence of target mammalian cells. We have found that recombinant human lactoferrin impairs the function of this system in two model organisms: Shigella and Enteropathogenic E. coli (EPEC). In the case of Shigella, there is loss and degradation of two proteins secreted by the type III mechanism, invasion plasmid antigens B and C (IpaB and IpaC); these proteins normally form a complex that causes Shigella to be taken up by host mammalian cells. In the case of EPEC, lactoferrin causes loss and degradation of E. coli secreted proteins A, B and D (EspABD) particularly EspB. These proteins are components of type III machinery and are known to be key elements of EPEC pathogenesis. Studies using purified EspB demonstrated that lactoferrin has a direct proteolytic effect on EspB that can be prevented by serine protease inhibitors. A synthetic peptide of the N-terminal 33 amino acids of lactoferrin caused loss of cell associated EspB but, unlike the whole lactoferrin molecule, did not caused degradation of EspB. Thus, in both model systems, brief exposure to lactoferrin causes loss and degradation of type III secretion system virulence proteins.
Similar content being viewed by others
References
Blocker A, Gounon P, Larquet E et al. 1999. The tripartite type III secretion of S. flexneri inserts IpaB and IpaC into host membranes. J Cell Biol 147, 683-93.
Brandenburg K, Jurgens G, Muller M et al. 2001. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol Chem 382, 1215-25.
Buttner D, Bonas U. 2002. Port of entry-the type III secretion translocon. Trends Microbiol 10, 186-92.
Feldman MF, Cornelis GR. 2003. The multitalented type III chaperones: all you can do with 15 kDa. FEMS Microbiol Lett 219, 151-8.
Gomez HF, Herrera-Insua I, Siddiqui MM et al. 2001. Protective role of human lactoferrin against invasion of Shigella flexneri M90T. Adv Exp Med Biol 501, 457-67.
Gomez HF, Ochoa TJ, Herrera-Insua I et al. 2002. Lactoferrin protects rabbits from Shigella flexneri-induced inflammatory enteritis. Infect Immun 70, 7050-3.
Gomez HF, Ochoa TJ, Carlin LG et al. 2003. Human lactoferrin impairs virulence of Shigella flexneri. J Infect Dis 187, 87-95.
Jarvis KG, Giron JA, Jerse AE et al. 1995. Enteropathogenic Escherichia coli contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. Proc Natl Acad Sci (USA) 92, 7996-8000.
Kaniga K, Trollinger D, and Galan JE. 1995. Identification of two targets of the type III protein secretion system encoded by the inv and spa loci of Salmonella typhimurium that have homology to the Shigella IpaD and IpaA proteins. J Bacteriol 177, 7078-7085.
Ochoa TJ, Noguera-Obenza M, Ebel F et al. 2003. Lactoferrin impairs type III secretory system function in Enteropathogenic Escherichia coli. Infect Immun, 71, 5149-5155.
Ward PP, Piddington CS, Cunningham GA et al. 1995. A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. Biotechnology 13, 498-503.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ochoa, T.J., Clearly, T.G. Lactoferrin disruption of bacterial type III secretion systems. Biometals 17, 257–260 (2004). https://doi.org/10.1023/B:BIOM.0000027701.12965.d4
Issue Date:
DOI: https://doi.org/10.1023/B:BIOM.0000027701.12965.d4